资讯

Nasdaq5 年
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication ... - Nasdaq
Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved its supplemental New Drug Application for EUCRISA ® ointment, 2%, extending the lower age limit from 24 months ...
Monthly Prescribing Reference8 年
Eucrisa Gains FDA Approval for Atopic Dermatitis - MPR
The Food and Drug Administration (FDA) has approved Eucrisa ... Eucrisa will be available as a 2% ointment. For more information call (650) 543-7500 or visit Pfizer.com.
Nasdaq5 年
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants
Pfizer Inc. PFE announced that the FDA has approved a supplemental new drug application (sNDA) for its eczema drug, Eucrisa (crisaborole) ointment, 2%. The sNDA sought label expansion of Eucrisa ...
Yahoo Finance5 年
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants - Yahoo Finance
Pfizer Inc. PFE announced that the FDA has approved a supplemental new drug application (sNDA) for its eczema drug, Eucrisa (crisaborole) ointment, 2%. The sNDA sought label expansion of Eucrisa ...
Yahoo Finance5 年
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants - Yahoo Finance
Pfizer Inc. PFE announced that the FDA has approved a supplemental new drug application (sNDA) for its eczema drug, Eucrisa (crisaborole) ointment, 2%. The sNDA sought label expansion of Eucrisa for ...
Monthly Prescribing Reference5 年
Crisaborole Ointment 2% Evaluated in Younger Patients With Atopic Dermatitis - MPR
Top-line results from the CrisADe CARE 1 phase 4 trial showed that crisaborole ointment 2% (Eucrisa; Pfizer) was well-tolerated in children aged 3 months to less than 24 months with mild to ...
Business Insider3 年
Padagis Confirms First-to-File Patent Challenge For Generic Version Of Eucrisa®
ALLEGAN, Mich., Sept. 28, 2021 /PRNewswire/ -- Padagis announced today that Anacor Pharmaceuticals, Inc initiated patent litigation on September 24, 2021 in the U.S. District Court for the ...
Mena FN3 年
Padagis Confirms First-to-File Patent Challenge For Generic Version Of Eucrisa® - MENAFN.COM
ALLEGAN, Mich., Sept. 28, 2021 /PRNewswire/ -- Padagis announced today that Anacor Pharmaceuticals, Inc initiated patent litigation on September 24, ...
Healio1 年
Crisaborole ointment effective as long-term maintenance therapy for atopic dermatitis - Healio
Once-daily crisaborole ointment 2% may be an effective and well-tolerated long-term maintenance therapy for pediatric and adult patients with mild to moderate atopic dermatitis, according to a ...
Yahoo Style UK6 年
Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis - Yahoo Life UK
Pfizer Inc. PFE announced top-line results from a late-stage study, which evaluated its PDE4 inhibitor, Eucrisa (crisaborole ointment, 2%), for the treatment of mild to moderate atopic dermatitis (AD) ...
Business Insider6 年
EUCRISA™ (crisaborole) Now Available in Canada - Markets Insider
EUCRISA™ is a new, steroid-free, topical ointment for mild to moderate atopic dermatitis (eczema) 1 First prescription treatment indicated for mild to moderate AD to be approved in more than 10 ...